Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis

BACKGROUND: Immune checkpoint inhibitors (ICIs), antibodies targeting PD-1 (programmed cell death protein 1)/PD-L1 (programmed death-ligand 1) or CTLA4 (cytotoxic T-lymphocyte–associated protein 4), have revolutionized cancer management but are associated with devastating immune-related adverse events including myocarditis. The main risk factor for ICI myocarditis is the use of combination PD-1 and CTLA4 inhibition. ICI myocarditis is often fulminant and is pathologically characterized by myocardial infiltration of T lymphocytes and macrophages. Although much has been learned about the role of T-cells in ICI myocarditis, little is understood about the identity, transcriptional diversity, and functions of infiltrating macrophages. METHODS: We used an established murine ICI myocarditis model (Ctla4+/–Pdcd1–/– mice) to explore the cardiac immune landscape using single-cell RNA-sequencing, immunostaining, flow cytometry, in situ RNA hybridization, molecular imaging, and antibody neutralization studies. RESULTS: We observed marked increases in CCR2 (C-C chemokine receptor type 2)+ monocyte-derived macrophages and CD8+ T-cells in this model. The macrophage compartment was heterogeneous and displayed marked enrichment in an inflammatory CCR2+ subpopulation highly expressing Cxcl9 (chemokine [C-X-C motif] ligand 9), Cxcl10 (chemokine [C-X-C motif] ligand 10), Gbp2b (interferon-induced guanylate-binding protein 2b), and Fcgr4 (Fc receptor, IgG, low affinity IV) that originated from CCR2+ monocytes. It is important that a similar macrophage population expressing CXCL9, CXCL10, and CD16α (human homologue of mouse FcgR4) was expanded in patients with ICI myocarditis. In silico prediction of cell-cell communication suggested interactions between T-cells and Cxcl9+Cxcl10+ macrophages via IFN-γ (interferon gamma) and CXCR3 (CXC chemokine receptor 3) signaling pathways. Depleting CD8+ T-cells or macrophages and blockade of IFN-γ signaling blunted the expansion of Cxcl9+Cxcl10+ macrophages in the heart and attenuated myocarditis, suggesting that this interaction was necessary for disease pathogenesis. CONCLUSIONS: These data demonstrate that ICI myocarditis is associated with the expansion of a specific population of IFN-γ–induced inflammatory macrophages and suggest the possibility that IFN-γ blockade may be considered as a treatment option for this devastating condition.

[1]  C. Morélot-Panzini,et al.  Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. , 2023, Cancer discovery.

[2]  D. Hughes,et al.  Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis , 2022, Cell reports.

[3]  J. Neal,et al.  Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis , 2022, Circulation.

[4]  P. Muñoz,et al.  Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity , 2022, Journal of experimental & clinical cancer research : CR.

[5]  John O. Prior,et al.  68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis , 2021, Journal for ImmunoTherapy of Cancer.

[6]  D. Schadendorf,et al.  Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. , 2021, European heart journal.

[7]  P. Funchain,et al.  Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms , 2021, Frontiers in Cardiovascular Medicine.

[8]  L. Heinzerling,et al.  Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation , 2021, Cancers.

[9]  Jing Wang,et al.  A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. , 2020, Cancer discovery.

[10]  Z. Qin,et al.  Temporary blockade of interferon-γ ameliorates doxorubicin-induced cardiotoxicity without influencing the anti-tumor effect. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  Lihua Zhang,et al.  Inference and analysis of cell-cell communication using CellChat , 2020, Nature Communications.

[12]  Hannah L Williams,et al.  Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy , 2020, Cell.

[13]  R. Gropler,et al.  Targeted PET Imaging of Chemokine Receptor 2–Positive Monocytes and Macrophages in the Injured Heart , 2020, The Journal of Nuclear Medicine.

[14]  D. Pisetsky,et al.  Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors , 2019, Rheumatology.

[15]  Douglas B. Johnson,et al.  Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. , 2019, The New England journal of medicine.

[16]  P. Sapra,et al.  Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors , 2019, Clinical Cancer Research.

[17]  Yi Su,et al.  Molecular Imaging Visualizes Recruitment of Inflammatory Monocytes and Macrophages to the Injured Heart , 2019, Circulation research.

[18]  D. Pe’er,et al.  Characterization of cell fate probabilities in single-cell data with Palantir , 2019, Nature Biotechnology.

[19]  I. Blasig,et al.  Doxorubicin‐induced cardiotoxicity involves IFNγ‐mediated metabolic reprogramming in cardiomyocytes , 2019, The Journal of pathology.

[20]  Maxim N. Artyomov,et al.  Tissue Resident CCR2− and CCR2+ Cardiac Macrophages Differentially Orchestrate Monocyte Recruitment and Fate Specification Following Myocardial Injury , 2019, Circulation research.

[21]  M. Zaidi,et al.  The Interferon-Gamma Paradox in Cancer. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[22]  F. Ginhoux,et al.  Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction , 2018, Nature Immunology.

[23]  M. Nahrendorf,et al.  Cardioimmunology: the immune system in cardiac homeostasis and disease , 2018, Nature Reviews Immunology.

[24]  D. Kreisel,et al.  The Human Heart Contains Distinct Macrophage Subsets with Divergent Origins and Functions , 2018, Nature Medicine.

[25]  Sumanth D. Prabhu,et al.  CCR2+ Monocyte-Derived Infiltrating Macrophages Are Required for Adverse Cardiac Remodeling During Pressure Overload , 2018, JACC. Basic to translational science.

[26]  Hideo Baba,et al.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.

[27]  J. Wolchok,et al.  Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Rong Chen,et al.  Angiotensin II–C–C chemokine receptor2/5 axis‐dependent monocyte/macrophage recruitment contributes to progression of experimental autoimmune myocarditis , 2017, Microbiology and immunology.

[29]  D. Bonaduce,et al.  Cardiotoxicity of immune checkpoint inhibitors , 2017, ESMO Open.

[30]  J. Aerts,et al.  SCENIC: Single-cell regulatory network inference and clustering , 2017, Nature Methods.

[31]  J. Seidman,et al.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.

[32]  F. Zouein,et al.  The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart , 2016, Journal of immunology research.

[33]  Hussein Tawbi,et al.  Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy , 2016, Journal of Immunotherapy for Cancer.

[34]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[35]  D. Mann,et al.  Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart , 2014, Proceedings of the National Academy of Sciences.

[36]  G. Randolph,et al.  Origin and functions of tissue macrophages. , 2014, Immunity.

[37]  Ansuman T. Satpathy,et al.  Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. , 2014, Immunity.

[38]  S. Moestrup,et al.  CD163-L1 Is an Endocytic Macrophage Protein Strongly Regulated by Mediators in the Inflammatory Response , 2012, The Journal of Immunology.

[39]  T. Okazaki,et al.  PD-1 deficiency results in the development of fatal myocarditis in MRL mice. , 2010, International immunology.

[40]  Y. Talke,et al.  Targeting of Gr-1+,CCR2+ monocytes in collagen-induced arthritis. , 2007, Arthritis and rheumatism.

[41]  R. Rabin,et al.  CXCR3 Is Induced Early on the Pathway of CD4+ T Cell Differentiation and Bridges Central and Peripheral Functions 12 , 2003, The Journal of Immunology.

[42]  P. Hokland,et al.  Interferon enhances the antibody-dependent cellular cytotoxicity (ADCC) of human polymorphonuclear leukocytes. , 1981, Journal of immunology.

[43]  Jennifer L. Guerriero Macrophages: Their Untold Story in T Cell Activation and Function. , 2019, International review of cell and molecular biology.

[44]  T. O’Toole,et al.  Myeloid cells as effector cells for monoclonal antibody therapy of cancer. , 2014, Methods.